Business
Notice of 2025 Annual General Meeting
Allergy Therapeutics plc has published its Notice of Annual General Meeting, seeking shareholder approval for two new board appointments: Helge Weiner-Trapness as Executive Director and Chief Strategy Officer, and Lawrence Allen Wang as Non-Executive Director. These appointments are intended to support the company's exploration of a dual primary listing on the Hong Kong Stock Exchange and its expansion into Asia. Mr. Weiner-Trapness brings over 30 years of experience from major investment banks, while Mr. Wang has over 20 years of healthcare and investment experience, including successfully listing Adicon on the Hong Kong Stock Exchange. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\")\n \nNotice of 2025 Annual General Meeting\n \n06 January 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, has today published its Notice of Annual General Meeting following publication of the Annual Report and Accounts for the year ended 30 June 2025 (the \"2025 Accounts\"). The Notice of Annual General Meeting has been posted to shareholders of the Company (the \"Shareholders\") today and is available to view on, and download from, the Company's website at https://www.allergytherapeutics.com/investors/shareholder-services/agm-information/.\nApproval of new appointments to Board\n \nThe Company is seeking shareholder approval to appoint two additional directors to the Board, as detailed below, each of whom brings decades of expertise in their respective fields. The Board believes these appointments will directly support the Group's current explorations of a potential dual primary listing on the Hong Kong Stock Exchange, alongside its existing listing on the London Stock Exchange's AIM market, and the ambition to expand Allergy Therapeutics' presence in Asia and become a global leader in allergy treatments. The proposed appointments of the additional directors remain subject to completion of customary due diligence and will be effective upon receipt of shareholder approval at the Annual General Meeting. A further announcement will be made in due course, as required.\n \nHelge Weiner-Trapness - Executive Director and Chief Strategy Officer\n \nUntil 2025, Mr Weiner-Trapness held the role of Vice Chairman, Global Banking, at HSBC, one of the world's largest financial organisations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. Prior to this, he was a Founding Partner of Hong Kong-based Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. With earlier, senior positions at Barclays Bank, Asia Pacific Land, JP Morgan Securities and Goldman Sachs, Mr Weiner-Trapness brings more than 30 years of experience across some of the world's biggest investment banks in the US and Asia.\n \nIn the newly cr...